The webinar will feature presentations from Key Opinion Leaders (KOLs) Ernest E. Moore, MD (Denver Health) and Gregory A. Magee, MD (Keck Medicine – USC) who will discuss the current treatment landscape and unmet medical need in the vascular trauma field.

Humacyte’s Human Acellular Vessels™ (HAV™) are investigational engineered off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement. HAV eliminates the need for harvesting a vessel from a patient or using a synthetic graft, and clinical evidence suggests that it is non-immunogenic and infection-resistant and can become durable living tissue. The webinar will include discussion of recent data on HAV as a potential treatment approach in the repair of vascular trauma injuries.

A question and answer session will follow the formal presentations.